Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
04:15pm, Tuesday, 03'rd Mar 2026
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Cir
The Market Isn’t Flat. It’s Rotating – And AI Is the Trigger
12:00am, Tuesday, 03'rd Mar 2026
AI is driving a massive stock market rotation. Why software stocks are falling - and hard assets are suddenly winning.
Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash
04:28pm, Monday, 02'nd Mar 2026
Moderna ( MRNA ) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50.
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
08:50am, Monday, 02'nd Mar 2026
Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.
These Dividend ETFs Pay More Than 10-Year Treasury Bonds
08:40am, Monday, 02'nd Mar 2026
If you purchase a 10-year U.S. Treasury bond, you'll get an annual yield of around 4%.
Moderna, Inc. $MRNA Shares Purchased by Banco Santander S.A.
05:00am, Saturday, 28'th Feb 2026
Banco Santander S.A. raised its stake in Moderna, Inc. (NASDAQ: MRNA) by 22.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned
Moderna's Covid-Flu Vaccine Recommended for Approval in EU
07:23am, Friday, 27'th Feb 2026
The recommendation from regulators paves the way for the shot's approval in the European Union at a time the company is facing scrutiny in the U.S.
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive
Moderna gets EU regulator nod for combined COVID, flu vaccine
06:09am, Friday, 27'th Feb 2026
Europe's medicines regulator on Friday recommended granting marketing authorisation to mCombriax, making Moderna's messenger RNA vaccine the world's first combined shot for people aged 50 and older ag
Moderna's Ups and Downs: Here's What You Need to Know Before Investing.
08:15am, Wednesday, 25'th Feb 2026
Moderna has faced good and bad times in recent years. Most recently, the FDA refused to review Moderna's flu candidate -- then reversed course.
Moderna Stock: How Far Can The Flu Shot Fly?
10:40am, Tuesday, 24'th Feb 2026
Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has in
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear
09:00am, Monday, 23'rd Feb 2026
Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line.
Weekend Morning Brew: Amazon tops Walmart; Meta--Nvidia pact
07:37am, Saturday, 21'st Feb 2026
Weekly Market HighlightsWeekly performance was volatile at the extremes, with 876 stocks gaining more than 10% while 776 stocks declined by more than 10%.Marke
